Tagged with Roundup

China Healthcare Weekly – 2nd September 2025
China: Chinese Pharma Turns to Local Reagent Suppliers; GSK Inks 12-Drug Deal with Hengrui
US Pharma Roundup: Vinay Prasad Returns to FDA; Vaccine Task Force Revived
US Pharma: FDA Appoints New CDER Director; AstraZeneca Pledges $50B; Moderna Scraps Japan Plant; Sarepta Defies FDA; Measles Spurs R&D Revival
UK Pharma: Life Sciences Strategy on the Rocks; Sanofi Buys Vicebio; AstraZeneca Looks Stateside
BeNeLux: UCB Mulls US Manufacturing Investment; EUR 200m for Dutch Biotech Startups; Call for Fast-Track of EU Financing & Innovation Reforms
LatAm: USD 560 million of Pharma Investment in Mexico; Measles on the Rise; Hypera Stakeholder Alliance in Brazil
MEA: Gypto Pharma Partners with Dawa to Reinforce Egyptian Production; Hikma Invests USD 1 Billion in US-Based Operations
China: Sciwind Confirms Obesity Ambitions with Positive Phase III Readout; FDA Blocks Cell Exports to China
France: Sanofi Snags Blueprint; Servier Turns to China; Owkin Aims to Accelerate R&D 20x with AI
Germany: Merck Picks Up SpringWorks; BMS Grabs Stake in BioNTech Immuno-Oncology Asset
UK: AstraZeneca Snags Cell Pioneer EsoBiotec; UK Pharma Awaits US-UK Trade Deal Outcome
We use cookies to ensure that we give you the best experience on our site. For more info

See our Cookie Privacy Policy Here